Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact

← All drugs

Humalog

Insulin Lispro

An injectable fast-acting insulin analogue used to manage high blood sugar levels in patients with diabetes.

Rapid-acting insulin ↗ Not in shortage
Generic name
Insulin Lispro
Brand name
Humalog
Route
Intravenous, Subcutaneous
Marketed by
Eli Lilly
FDA pharmacologic class
Insulin Analog
First FDA approval
14 Jun 1996

Where Insulin Lispro is approved

All regulators →

Of the three regulators tracked here, the first to approve Insulin Lispro was the EU, on 30 Apr 1996. It is approved in 3 of the 3 regulators tracked here.

USUnited States (FDA)
14 Jun 1996
Humalog Kwikpen
BLA020563 on Drugs@FDA
First original NDA/BLA approval
EUEuropean Union (EMA)
30 Apr 1996
Humalog
EMA product page
First centralised authorisation
CACanada (Health Canada)
8 Oct 1996
Humalog (cartridge)
Notice of Compliance 6514
First new-drug NOC

From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.

What health systems spend on Insulin Lispro

All medicines →
ENNHS England
£24.3m
498,822 items dispensed, Aug 2025 to Jul 2026
+0% on the previous 12 months
Net ingredient cost, community prescriptions
USUS Medicaid
$453.5m
2,373,609 prescriptions in 2025 · Insulin Lispro, Humalog, Admelog
-1% on 2024
Amount Medicaid reimbursed, before rebates

From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.

How Insulin Lispro works

All drug targets →
  • Insulin receptor agonist Agonist
    Target: INSR insulin receptor
    ChEMBL only
Diseases it has been tested for in clinical trials, by furthest phase
  • HyperglycemiaPhase 3
  • HypoglycemiaPhase 3
  • Sjogren syndromePhase 3
  • Chronic kidney diseasePhase 3
  • Prediabetes syndromePhase 3
  • Type 1 diabetes mellitusPhase 3
  • Type 2 diabetes mellitusPhase 3
  • Gestational diabetesPhase 2
  • Glucose metabolic processPhase 1

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1201538, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

Patient leaflets for Insulin Lispro

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Reference identifiers for Insulin Lispro

ATC codes
A10AD04, A10AC04, A10AB04
ChEMBL
CHEMBL1201538
DrugBank
DB00046
PubChem CID
168324401
CAS number
133107-64-9
FDA UNII
GFX7QIS1II
Wikidata
Q3492616
Wikipedia
Insulin lispro

Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.

What Humalog is used for

HUMALOG is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. HUMALOG is a rapid acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ( 1 )

How it works

12.1 Mechanism of Action Regulation of glucose metabolism is the primary activity of insulins and insulin analogs, including insulin lispro. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis.

Compare Humalog with

Explore more

How this page is built

The facts on this page are pulled directly from official U.S. FDA datasets — they are not written from memory. Each field below names the dataset it came from, so you can check it yourself.

Plain-English summaries and drug-class explainers are written and reviewed by Sreepriya Prasannan (MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany). Data is retrieved automatically from the sources above and cross-checked with AI-assisted verification (Anthropic's Claude) — brand and generic names are matched against the exact FDA product record so that a combination product or a different formulation cannot be mistaken for the drug on this page. An editor reviews the result before publication. We describe this in full in our editorial standards and corrections policy. The FDA data on this page was last retrieved on 10 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.